Trial Profile

Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
Indications Respiratory syncytial virus infections
Focus Adverse reactions; First in man
Sponsors GlaxoSmithKline; GSK

Most Recent Events

29 Jul 2022 Results published in the Journal of Infectious Diseases
15 Dec 2020 Status changed from active, no longer recruiting to completed.
25 Oct 2020 Results assessing immunogenicity of different formulations of an investigational vaccine (RSVPreF3) in young and older adults presented at the IDWeek 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com